Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia

Journal of the American College of Cardiology

Volumn 37, Issue 2, 2001, Pages 616-623

  Sato, Kaori ^a   Wu, Tiangen ^a   Laham, Roger J ^a   Johnson, Robert B ^a   Douglas, Pamela ^a   Li, Jianyi ^a   Sellke, Frank W ^a   Bunting, Stuart ^b   Simons, Michael ^a   Post, Mark J ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b GENENTECH INC   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN;

ANGIOCARDIOGRAPHY; ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG POTENCY; HEART MUSCLE ISCHEMIA; HYPOTENSION; IMMUNOMODULATION; INTRACORONARY INFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANIMALS; CORONARY CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; LYMPHOKINES; MALE; MICROCIRCULATION; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; SWINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035131299     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)01144-X     Document Type: Article

References (31)

1. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial
2. Induction of neoangiogenesis in ischemic myocardium by human growth factors
3. Double blind placebo controlled trial of recombinant human vascular endothelial growth factor-the VIVA trial
4. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
5. Vascular endothelial growth factor administration in chronic myocardial ischemia
6. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury
7. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs
8. VEGF administration in chronic myocardial ischemia in pigs
9. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts
10. Hemodynamic effects of intracoronary VEGF delivery: Evidence of tachyphylaxis and NO dependence of response
11. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance
12. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis
13. Nitric oxide mediates angiogenesis induced in vivo by platelet-activating factor and tumor necrosis factor-alpha
14. Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro
15. Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: A comparison of angiographic, echocardiographic and coronary flow parameters
16. Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia
17. Local perivascular administration of basic fibroblast growth factor: Drug delivery and toxicological evaluation
18. Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium
19. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity
20. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis
21. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
22. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
23. Vascular permeability factor/vascular endothelial growth factor, microvascular hyper-permeability, and angiogenesis
24. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
25. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation
26. Vascular endothelial growth factor vascular/permeability factor produces nitric oxide dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium
27. Distribution and metabolism of N(G)-nitro-L-arginine methyl ester in patients with septic shock
28. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia
29. VEGF upregulates ecNOS message, protein, and no production in human endothelial cells
30. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR)